The U.S. Food and Drug Administration issued a warning letter to Simtra Biopharma Solutions after an inspection revealed significant contamination-related GMP violations at its sterile manufacturing facility in Halle, Germany. Inspectors identified repeated microbial recoveries, aseptic processing failures, and weak
